Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | ESR2 | Q92731 | 7/20 | 0.47 |
| ▸ | ESR1 | P03372 | 5/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL43080 | 0.95 | SLC18A3 (0.56) | SLC18A3ALDH1A1LMNATP53MAPT | |
| SCHEMBL346325 | 0.92 | LMNA (0.59) | SLC18A3ALDH1A1LMNATP53MAPT | |
| SCHEMBL8025878 | 0.92 | LMNA (0.59) | SLC18A3ALDH1A1LMNATP53MAPT | |
| SCHEMBL28722738 | 0.92 | LMNA (0.59) | SLC18A3ALDH1A1LMNATP53MAPT | |
| SCHEMBL1405569 | 0.89 | ESR2 (0.50) | SLC18A3ALDH1A1LMNATP53MAPT | |
| SCHEMBL18117721 | 0.86 | MAPT (0.54) | SLC18A3ALDH1A1LMNATP53MAPT | |
| SCHEMBL5886587 | 0.86 | ESR2 (0.56) | LMNAMAPTESR2ESR1CYP3A4 | |
| Bicarbonate SCHEMBL9685458 | 0.84 | SLC18A3 (0.53) | SLC18A3ALDH1A1LMNATP53MAPT | |
| SCHEMBL5148273 | 0.83 | ESR2 (0.60) | LMNAESR2ESR1CYP3A4CYP2D6 | |
| SCHEMBL21568471 | 0.83 | ALDH1A1 (0.41) | SLC18A3ALDH1A1LMNATP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298387-A1 | IL-8 Receptor Antagonists | SMITHKLINE BEECHAM CORPORATION | 2010-11-25 | — | — | US | claimed |
| EP-2099300-A1 | IL-8 RECEPTOR ANTAGONISTS | SmithKline Beecham Corporation (US) | 2009-09-16 | — | — | EP | claimed |
| WO-2008070707-A1 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-06-12 | — | — | WO | claimed |
| EP-3878446-A1 | HSD11B1 INHIBITORS FOR USE IN IMMUNOTHERAPY AND USES THEREOF | UNIVERSITE DE GENEVE (CH) | 2021-09-15 | — | — | EP | disclosed |
| CN-109206444-A | Photic contraction metal organic framework compound | 苏州大学 | 2019-01-15 | — | — | CN | disclosed |
| CN-108699048-A | Oxadiazolamide derivative compounds as histone deacetylase 6 inhibitors and pharmaceutical compositions comprising the same | 株式会社钟根堂 | 2018-10-23 | — | — | CN | disclosed |
| CN-108623425-A | Method for constructing four-membered ring by visible light catalysis [2+2] reaction | 中国科学院理化技术研究所 | 2018-10-09 | — | — | CN | disclosed |
| US-8044075-B2 | IL-8 receptor antagonists | GLAXOSMITHKLINE (US) | 2011-10-25 | — | — | US | disclosed |
| US-20100298387-A1 | IL-8 Receptor Antagonists | SMITHKLINE BEECHAM CORPORATION | 2010-11-25 | — | — | US | disclosed |
| EP-2099300-A1 | IL-8 RECEPTOR ANTAGONISTS | SmithKline Beecham Corporation (US) | 2009-09-16 | — | — | EP | disclosed |
| WO-2008117148-A1 | SUBSTITUTED OXADIAZOLE ANALOGS AS CALCIUM CHANNEL ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2008-10-02 | — | — | WO | disclosed |
| WO-2008070707-A1 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298387-A1 | IL-8 Receptor Antagonists | CXCL8, CCR8, IL1RN | SLC18A3 2637/4885ALDH1A1 2969/4885LMNA 4383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.